SNO 2018: Bevacizumab Prolongs PFS in Recurrent GBM, and Initial Response May Be a Good Prognostic Factor
A literature review and meta-analysis, as well as a retrospective analysis, evaluated PFS and short-term bevacizumab, respectively.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.